Observing atrial fibrillation in cancer patients
Multicenter International Prospective Registry to Identify Major Cardiovascular Events Associated With the Occurrence of Atrial Fibrillation in Active Cancer Patients
This study is tracking heart rhythm problems in cancer patients to see how they affect their health over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Caen Academic / other |
| Locations | 1 site (Caen, Normandy) |
| Trial ID | NCT04696081 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a prospective multicenter international registry of adult patients with active cancer who are experiencing atrial fibrillation. It will track the occurrence of major cardiovascular events over a one-year follow-up period. The study focuses on understanding the implications of atrial fibrillation in the context of cancer treatment and its potential complications. By gathering data from multiple centers, the study seeks to fill gaps in knowledge regarding this common complication in cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adult patients with active cancer diagnosed within the last six months who have experienced at least one episode of atrial fibrillation.
Not a fit: Patients receiving palliative care or those with a history of long-standing persistent or permanent atrial fibrillation prior to cancer diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and treatment strategies for cancer patients experiencing atrial fibrillation.
How similar studies have performed: While the specific approach of this study is novel, there is a growing body of literature addressing atrial fibrillation in cancer patients, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients * outpatients or hospitalized patients * with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment) * at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis) * in sinus rhythm at the time of cancer diagnosis Exclusion Criteria: * patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence) * history of long-standing persistant or permanent AF prior to cancer diagnosis
Where this trial is running
Caen, Normandy
- Alexandre — Caen, Normandy, France (Recruiting)
Study contacts
- Principal investigator: Joachim Alexandre, MD, PhD — Caen Normandy University Hospital, France
- Study coordinator: Joachim Alexandre, MD, PhD
- Email: alexandre-j@chu-caen.fr
- Phone: +330231064770
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.